Theravance Biopharma Inc. (TBPH) shares plunged 28% in pre-market trading after the company announced that its hypertension drug failed to meet the primary endpoint in a pivotal late-stage clinical trial.

This disappointing trial result directly triggered a significant sell-off in the market. As the drug failed to achieve the preset efficacy endpoint, the company announced it would immediately conduct a comprehensive evaluation of the development project for this hypertension medication and plans to initiate a strategic review of the company’s overall pipeline. The purpose of this strategic assessment is to reallocate R&D resources and evaluate future development paths.